Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
Tango faces a fresh PRMT5 competitor
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
